|
|
つくばリポジトリ (Tulips-R) >
0 コンテンツタイプ別 (Content type) >
01 雑誌発表論文等 (Journal article, etc.) >
Experimental animals >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/2241/115778
|
| Title: | A Novel Diabetes Mellitus Mouse Model, MAFA-Deficient and Beta Cell-Specific MAFK-Overexpressing Hybrid Transgenic Mice, Developed Severe Diabetic Nephropathy and Improved with TCV-116 (Candesartan Cilexetil) Treatment |
| Authors: | FUJITA, Akiko
YOH, Keigyou
SHIMOHATA, Homare
MORITO, Naoki
OJIMA, Masami
OKAMURA, Midori
TAKAHASHI, Satoru
YAMAGATA, Kunihiro
楊, 景堯
森戸, 直記
高橋, 智
山縣, 邦弘 |
| Issue Date: | Jan-2012 |
| Publisher: | Japanese Association for Laboratory Animal Science |
| Journal Title: | Experimental animals |
| Volume: | 61 |
| Issue: | 1 |
| Start Page: | 49 |
| End Page: | 57 |
| DOI: | 10.1538/expanim.61.49 |
| PMID: | 22293672 |
| Abstract: | Many models of diabetic nephropathy have been reported. However, it is rare that the characteristic findings of severe human diabetic nephropathy, such as diffuse, nodular, and exudative lesions, are all detected in one model mouse. Previously, we reported that MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic (Mafa–/–Mafk +) mice develop diabetes mellitus and, after uninephrectomy, demonstrate these characteristic lesions. In this study, we administered TCV-116 (candesartan cilexetil) to Mafa–/–Mafk + mice after uninephrectomy and examined whether TCV-116 ameliorated the diabetic nephropathy. We also evaluated the utility of these mice as a model for developing treatments for diabetic nephropathy. We performed uninephrectomy of the Mafa–/–Mafk + mice at 8 weeks old. We then divided these mice into two groups as follows: 1) an untreated group and 2) a group treated with TCV-116 at 5 μg/g/day from 10 to 20 weeks. TCV-116 treatment did not affect serum glucose levels. However, in the treated group, urinary protein excretion, mesangial matrix expansion, enlargement of the kidney, and glomerular surface area were all improved relative to untreated mice. Oxidative stress is known to be increased in diabetic nephropathy and to be suppressed by TCV-116. The urinary level of 8-OHdG, an oxidative stress marker, at 20 weeks was lower in the TCV-116-treated group than in the untreated group. From these results, we concluded that the Mafa–/–Mafk + mouse is a useful model to analyze diabetic nephropathy and a useful tool for the development of new drugs to treat diabetic nephropathy. |
| URI: | http://hdl.handle.net/2241/115778 |
| Rights: | © 2012 Japanese Association for Laboratory Animal Science |
| Text Version: | publisher |
| Appears in Collections: | 楊 景堯 (Yoh Keigyou)
森戸 直記 (Morito Naoki)
高橋 智 (Takahashi Satoru)
山縣 邦弘 (Yamagata Kunihiro)
Experimental animals
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|
